Affordable HIV Prevention Shot Receives U.S. Approval
On Monday, November 2, 2026, the US Food and Drug Administration (FDA) granted tentative approval for a cost-effective generic version of lenacapavir, a revolutionary HIV prevention injection administered twice a year. Produced by Dr. Reddy's Laboratories, an Indian company, this generic medication will be priced at $40 per person annually in 120 low- and middle-income nations. This is a stark contrast to the brand-name alternative, Yeztugo, manufactured by Gilead Sciences, which has a staggering US list price of $28,218 per year. This approval marks a significant triumph for advocates of global health, although there are still critical access gaps that need to be addressed. Lenacapavir functions as a capsid inhibitor, targeting the protein shell that safeguards the virus's genetic material, effectively preventing its replication.Clinical trials have demonstrated its effectiveness, showing over 99.9% efficacy in preventing HIV transmission. Because Gilead retains the active pat...